Where does Meiji Seika Pharma Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Meiji Seika Pharma Co., Ltd. ranks #4,633 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Meiji Seika Pharma Co., Ltd. hold?

Meiji Seika Pharma Co., Ltd. holds 76 US utility patents granted between 2015 and 2025, spanning 28 technology areas.

What is Meiji Seika Pharma Co., Ltd.'s Innovation Score?

Meiji Seika Pharma Co., Ltd. has an Innovation Score of 41.0 out of 100 (top 34% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Meiji Seika Pharma Co., Ltd. focus on?

Meiji Seika Pharma Co., Ltd.'s top technology area is C07D (Heterocyclic Compounds) with 40 patents. Grants appear in 28 CPC subclasses total.

Is Meiji Seika Pharma Co., Ltd.'s patent grant rate increasing or decreasing?

Meiji Seika Pharma Co., Ltd.'s recent grant velocity is -62% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Meiji Seika Pharma Co., Ltd.'s patents?

Meiji Seika Pharma Co., Ltd.'s patents average 8.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Meiji Seika Pharma Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Meiji Seika Pharma Co., Ltd.

USPTO PatentsView assignee record - 76 granted patents across 28 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Meiji ranks #4,633 of 49,997 tracked US assignees by granted-patent volume, with 76 patents across 28 technology areas.

#4,633
of 49,997 US assignees by volume: Top 34%
by Innovation Score (41.0/100): 8.2
avg claims per patent: -62%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4633 · Foreign Corporation #4,633 · 76 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 76 grants
TOP-DECILE #4,633/49,997
PHOTO-FINISH KPR U S
CPC-FOCUS C07D · 28 areas
INNOV-PAR 41.0/100
CLAIMS-PAR 8.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -62% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: KPR U.S., LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Contec · near

41
H E F · near

41
Lamplight Farms… · near

41
Meiji Seika Pharma · this assignee

41
RAB Lighting · near

41
3D Lighting… · lowest

7

What this shows Meiji's Innovation Score is 41.0/100 (top 34% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Meiji's grants concentrate

Meiji Seika Pharma Co., Ltd. is a focused PatentsView assignee: 28 CPC subclasses with 52.6% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2018 (15 grants) versus a trough of 1 in 2023. By volume, Meiji sits between KPR U.S., LLC and Opex Corporation.

Meiji's three-year grant acceleration

Meiji Seika Pharma Co., Ltd. shows 6 grants in 2022–2024 against only 17 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

KPR U S

76
Kyushu Institute…

76
Livsmed

76
M&K Holdings

76
Medtronic Advance…

76
Nanjing Universit…

76
Nuvectra

76
Opex

76
Meiji Seika Pharma ◀

76

What this shows Meiji holds 76 patents at rank #4,633, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Meiji

By rank, the assignees closest to #4,633 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Meiji's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Meiji, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (41 here).

RAB Lighting Inc. 41 Contec, LLC 41 Lamplight Farms Incorporated 41 H.E.F. 41

Similar claim depth

Nearest assignees by average claims per patent (8.2 here).

Hitachi-Johnson Controls Air Conditioning, Inc. 8.2 avg Wapp Tech Corp. 8.2 avg Callaway Golf Company 8.2 avg Dr. Ing. h.c. F. Porsche AG 8.2 avg

Meiji's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

41 Top 34% higher than 66% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Meiji Seika Pharma Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	13	17.1%
2016	13	17.1%
2017	9	11.8%
2018	15	19.7%
2019	3	3.9%
2020	11	14.5%
2021	3	3.9%
2022	3	3.9%
2023	1	1.3%
2024	2	2.6%
2025partial year	3	3.9%

Which technologies does Meiji Seika Pharma Co., Ltd. patent most?

C07D - Heterocyclic Compounds 40

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 39

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 28

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 18

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 17

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 15

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 14

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 14

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 13

C12Y - Enzymes 13

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 7

C07C - Acyclic OR Carbocyclic Compounds 7

A23K - Fodder 7

Y02A - Technologies FOR Adaptation TO Climate Change 5

Y02E - Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution 5

Top 15 of 28 technology areas

Where it ranks

Overall rank by patents

#4,633

of 49,997 tracked assignees

Innovation Score

41.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Meiji Seika Pharma Co., Ltd.'s patent record in context - here's where to go next.

Meiji Seika Pharma Co., Ltd.'s lead technology class is C07D (Heterocyclic Compounds), 52.6% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #4,633 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Meiji Seika Pharma Co., Ltd. against KPR U.S., LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.